Introduction
The LEC-CAM/SELECTIN family of cell adhesion molecules mediates adhesive interactions between circulating leukocytes and the vascular endothelium (Stoolman, 1989; Geng et al., 1990) . These molecules participate in the recruitment of neutrophils and monocytes to inflammatory lesions (Carlos and Harlan, 1990; Jutila et al., 1989) in the adhesion of activated platelets to leukocytes (Larsen et al., 1989a) , in the recirculation of normal lymphocytes through the lymphoid system (Yednock and Rosen, 1989) , and in the hematogenous dissemination of lymphoid malignancies (Bartgatze et al., 1987) . Three structurally related receptors have thus far been identified: ELAM-1 (Bevilacqua et al., 1989 ) GMP-14OIPADGEM (Bonfanti et al., 1989; Johnston et al., 1989) , and LEC-CAM1 (consensus term referring to the antigen expressing the Mel14 epitope in the mouse [Bowen et al., 1989; Lasky et al., 19691 and its human homologs, LeWlGl [Camerini et al., 19891, LAM [Tedder et al., 19893, and DREG [Kishimoto et al., 19901) . The N-terminal domains of these molecules are homologous to one another and to a variety of calcium-dependent carbohydrate recognition domains (CRDs) containing a structural motif originally described by Drickamer and colleagues (Drickamer, 1988) . The CRD of LEC-CAM1 mediates adhesion to high endothelial venules in vitro (Geoffroy and Rosen, 1989; Yedneck and Rosen, 1989 ) and appears to initiate lymphocyte recirculation through binding to one or more sialylated ligands on the high endothelial venules in vivo (Rosen et al., 1985 (Rosen et al., , 1989 . The presence of a CRD in ELAM-1 therefore suggests that specific oligosaccharide determinants may constitute part or all of its endogenous ligand. The current study provides experimental support for this hypothesis by linking expression of a family of a(2,3)sialylated, a(l,3)fucosylated lactosaminoglycans at the cell surface to ELAMl-dependent endothelial adhesion and by demonstrating that transfection of a specific a(l3)fucosyltransferase cDNA into nonmyeloid cell lines results in the de novo expression of functional ligands for ELAM-l-mediated cell adhesion.
Results

ELAM-l-Dependent Ceil Adhesion Correlates with Slalyl Lewls x Expression in variants of the HL-60 Cell Line
The ELAM-1 receptor mediates the adhesion of neutrophils, monocytes, and the related cell lines HL-60 and U937 to cytokine-stimulated human umbilical vein endothelial cells (HUVECs) (Bevilacqua et al., 1987 (Bevilacqua et al., , 1989 . The surfaces of these leukocytic cells are unusually rich in fucosylated derivatives of neutral and a(2,3)sialylated polylactosamine ([Gal61, 4GlcNAc] ,) moieties (Fukuda et al., 1984 (Fukuda et al., , 1985 Spooncer et al., 1984) . The structurally and biosynthetically related members of this group include the sialyl Lewis x tetrasaccharide (NeuAcaP-+ Gal61 +4(Fucal+3) GlcNAc; slex; Fukushima et al., 1984; Figure lA) , its nonsialylated trisaccharide analog Lewis x (Gal81+4(Fucal+3)GlcNAc;
Lex or SSEA-1; Gooi et al., 1981; Figure lA) , and related neutral and a(2,3)sialic acidsubstituted structures containing single (VIM-2 [Macher et al., 1988] )or multiple(FH4, FH5 [Fukushi et al., 19841, and FH6 [Fukushi et al., 19851) internal a(l3)linked fucose residues. By contrast, these oligosaccharide determinants are generally not detected on circulating cells that lack the ligand(s) for ELAM-1 (Fox et al., 1983; Fukushima et al., 1984; Fukushi et al., 1985) . These observations prompted us to measure expression of sLex and Lex epitopes on two variants of the HL-60 line showing markedly different levels of ELAM-l-dependent adhesion to TNFa-treated HUVECs. Figure 2 depicts the added cells attached in the presence of the control antibody lgG2b. This adhesion was largely ELAM-1 dependent since only 11% of the cells adhered in the presence of the anti-ELAM-1 antibody BBll (Benjamin et al., 1990) . By contrast, the line designated HL-60 A exhibited a lower absolute level of adhesion (mean of 16%) that was not significantly reduced by treatment of the HUVECs with BBll (14%). Thus, HL-60A showed virtually no ELAM-l-dependent adhesion under conditions that optimized detection of this interaction on HUVEC monolayers. Flow cytometric analysis revealed markedly different levels of the slex and Lex determinants at the cell surface of HL-60 A and HL-60 B (Figure 28 ). Both cell lines expressed the Lex epitope as has been previously described for the HL-60 cell line (Symington et al., 1965) . By contrast, the slex epitope was detected on the adhesioncompetent HL-60 line B cells exclusively. The resistance of the ELAM-1 ligand(s) to paraformaldehyde fixation and the persistence of its functional activity at reduced temperature mirror the behavior of the endogenous, sialylated ligand for LEC-CAM1 (Stoolman, 1969; Yednock and Rosen, 1969) and thus are consistent with the hypothesis that the CRD of ELAM-1 interacts with an oligosaccharide on the surface of HL-60 cells. Moreover, the coordinate loss of both ELAM-l-dependent adhesion and the sLex determinant suggested that the ligand(s) belongs to the family of sialylated, fucosylated polylactosaminoglycans expressed at high levels on myeloid cells.
ELAM-l-Dependent
Cell Adhesion of COS-1 Cells Determined by Transfectlon of a Cloned Fucosyltransferase cDNA The profound differences in slex expression observed in the HL-60 variants may have resulted from differences in the activities of specific fucosyltransferases (Figure lA) , by analogy to the Chinese hamster ovary (CHO) glycosylation mutants Lecll and Lecl2 (Howard et al., 1967) . The Lecll mutant exhibits de novo expression of a specific a(1,3)fucosyltransferase, termed Fuc-TI, that determines the synthesis of surface-localized neutral and a(2,3)sialylated polylactosaminoglycans substituted with a(l,3)-linked fucose residues ( Figure 1A ). By contrast, the Lecl2 mutant expresses a distinct a(l,3)fucosyltransferase, FucTII, that determines surface display of neutral, a(1,3) fucosylated polylactosaminoglycans, but not the a(2,3) sialylated analogs ( Figure 1A ). The penultimate step in the biosynthesis of these structures, which include the sLex moiety, is thought to be catalyzed by a widely distributed sialyltransferase that attaches sialic acid in a(2,3)linkage to terminal galactose residues in the polylactosamine substrate (Weinstein et al., 1962 ). These sialylated molecules can then serve as acceptors for some (Holmes et al., 1966; Howard et al., 1967) but not all (Howard et al., 1967) a(l,3)fucosyltransferases.
These enzymes may add fucase residues in a(1,3)-linkage to the terminal GlcNAc residue, thus forming the sLex structure, and/or to one or more GlcNAc residues within internal lactosamine units (Holmes et al., 1966; Howard et al., 1967) . Likewise, a(1,3) fucosyltransferases can generate the Lex moiety and its polyfucosylated analogs from neutral polylactosamine precursors. These neutral fucosylated molecules are not, however, substrates for any known a(23)sialyltransferases. These considerations suggest a critical, regulatory role for expression of specific a(l,3)fucosyltransferases in the biosynthesis of the family of sialylated, fucosylated lactosaminoglycans that represent putative ELAM-1 ligands. To investigate this possibility, and to test the roles of these molecules in ELAM-l-dependent cell adhesion, we effected their de novo surface expression on mammalian host cells, via modification of their glycosylation pheno- types with transfected a(l,3)fucosyltransferase cDNAs or gene segments (pCDMFa(l,3/1,4)FT [Kukowska-Latallo et al., 19901, pCDNAl-a(l,3) L. et al., unpublished data] ). Nonmyeloid hosts were chosen for these experiments in order to isolate the role of the oligosaccharide molecules in ELAM-l-dependent adhesion from other myeloid-specific molecules known to participate in leukocyte-endothelial cell interactions (Springer, 1990) . COS-1 cells were used for the first of these experiments since these cells do not express detectable a(l,3)fucosyltransferase activity nor cell surface oligosaccharides that contain the cognate a(l,3)fucose linkages (Kukowska-Latallo et al., 1990) . Moreover, COS-1 cells do not exhibit ELAMl-dependent adhesive properties. They do, however, express the oligosaccharide substrates necessary for a(1,3) fucosyltransferase-dependent biosynthesis of the family of oligosaccharides represented by the Lex and slex molecules (Fukudaet al., 1988; Kukowska-Latallo et al., 1990) .
As shown in Figure Figure 3A ; data not shown). Using 51Cr-labeled cells, only pCDMFa(l,3/ 1,4)FT transfectants, expressing the four new fucosylated oligosaccharide determinants, exhibited adhesion to TNFatreated HUVECs ( Figure 3B ). This binding was substantially inhibited with the anti-ELAM-1 antibody BBll, but not with its isotype control antibody lgG2b, nor with antibodies that detect other polypeptides expressed on TNFatreated HUVECs (VCAMl, ICAMl, and HLA class I determinants; Figure 3C ).
In these experiments, approximately 7% of the pCDMF a(1,3/1,4)FT transfectants adhered to TNFa-treated endothelium, whereas 35% of normal neutrophils adhered under the same conditions (Figure 38, right) . This apparent difference in relative adhesion "activity" can be accounted for by the fact that only a minority (26%-310/b) of the radiolabeled COS-1 cells actually express new cell surface oligosaccharide determinants and by the fact that ELAM-1 interactions represent only one of several mechanisms responsible for adhesion of neutrophils to cytokinestimulated endothelium (Luscinska et al., 1989) . Indeed, anti-ELAM-1 antibody BBll pretreatment of the TNFa-activated HUVECs in this experiment incompletely blocked neutrophil adhesion, reducing it to approximately 17% (data not shown). These considerations indicate that ELAM-l-dependent adhesion of the two cell types is of a substantially similar magnitude.
The neutral and sLea isomers ( Figure 1B ) displayed by the pCDMFa(l,3/1,4)FT transfected, adhesion-competent COS-1 cells are generally absent from blood cells of the myeloid lineage (Fukuda et al., 1984 (Fukuda et al., , 1985 Spooncer et al., 1984; Dunstan, 1988 ) and thus would not normally participate in leukocyte-ELAM-1 adhesive interactions. We therefore tentatively concluded that the ELAM-l-dependent adherence of cells transfected with pCDMFa(lJ/ 1,4)FT is mediated by the surface-localized sLex tetrasaccharide molecule and/or its alternately and poly-a(l,3)fucosylated analogs, but not by the neutral family of molecules represented by the Lex determinant.
Expression of a Cloned Fucosyltransferase cDNA in Stably lkansfected CHO Cells Determines ELAM-lDependent Cell Adhesion and sLex Expression To isolate and further confirm the contribution of the sLextype oligosaccharide molecules to ELAM-l-dependent binding, we generated a transfected mammalian cell line (CHO-FT) that expresses surface-localized sLex and Lex determinants but not the Lea or sLea determinants. The parental CHO cell line Ade-C (Oates and Patterson, 1977; Van Keuren et al., 1988) chosen for these experiments expresses no detectable a(l,3)fucosyltransferase activity (Experimental Procedures) nor the corresponding Lex and sLex molecules (Smith et al., 1990) . It does, however, express polylactosaminoglycan precursors for these molecules but not for the Lea precursors (Smith et al., radiolabeled with 5rCr, harvested, and tested for adhesion on HUVEC monolayers using Method I, as detailed in Experimental
Procedures. Transfected cells were applied to either TNFa-treated (+) or untreated (-) HUVEC monolayers and allowed to adhere for 20 min prior to washing. Plasmids pCDM7-a(l,3/1,4)FT and pCDNAl-a(l,3)FT(labeled as in [A]) encode distinct a(l,3)fucosyltransferases as described in the text. The corresponding control vectors for these plasmids (pCDM7 and pCDNA1) lack cDNA inserts. Plasmid pCDM7-aGT encodes a murine a(l3)galactosyltransferase (Larsen et al., 1999b) . Plasmid pH3.4 encodes a human a(l,2)fucosyltransferase (Rajan et al., 1999) . COS-1 cells transfected with these latter two plasmids do not express Lex, slex, Lea, or sLea determinants (data not shown). The adhesion of normal neutrophils (PMN) to HUVEC within the same experiment is also shown on a separately scaled ordinate. (C) Specific anti-ELAM-1 blocking of adhesion of pCDM7-a(1,3/1,4)FT transfected cells to TNFa-treated HUVEC monolayers. 51Cr-labeled COW cells transfected with pCDM7-c(1,3/1,4)FT, or the pCDM7 control, were assessed in the adhesion assay as outlined in (B), except that the HUVEC monolayers had been pretreated with antibody directed against ELAM-1 (BBII), with an isotope control (IgG2b), or with antibodies against other endothelial-expressed .polypeptides (anti-VCAMI 489, anti-ICAMl, and anti-HLA class l), as described in Experimental
Procedures. Error bars equal one standard deviation. Wr-labeled CHO-FT cells were subjected to adhesion for 10 min, as outlined in(B), except that the HUVEC monolayers had been pretreated with the anti-ELAM-1 antibody BBll, the isotype control IgGPb, or with antibodies against VCAMl and HLA class 1 molecules, at the same concentrations used in Figure 32 . Pretreatment with antiICAMl fails to inhibit binding to TNFa-treated HUVEC monolayers (data not shown). Error bars equal one standard deviation. 1990). Expression of stably transfected pCDMba(l$/l,4)FT washing (Experimental Procedures). By contrast, control in this host determines surface display of substantial transfectants (CHOW) that do not express significant amounts of the sLex determinant, and to a lesser extent amounts of the Lex or slex molecules ( Figure 4A ) did not the Lex determinant, but not the Lea isomers ( Figure 4A ). exhibit significant binding to either TNFa-treated or unEach CHO transfectant line was assessed for adhesion treated HUVECs ( Figure 4B ) at early time points, and minito untreated and TNFa-treated HUVECs (Figures 48 and mal, nonspecific adhesion at later ones. Adhesion of 4C). Cells were allowed to adhere for between 5 and 25 CHO-FT cells was ELAM-1 dependent since it was inmin, before washing off unbound cells. CHO-FT cells exhibited by pretreatment of the HUVECs with the BBll antihibited marked adhesion to TNFa-treated HUVECs, but ELAM-1 antibody, but not by the control antibody lgG2b, not to untreated endothelium (Figures 48) . Adhesion of nor with antibodies directed against other adhesion re-CHO-FT cells was well-established within 5 min, plateaued ceptors (VCAMl and ICAMl), or to HLA class I determiat 10 min, and was resistant to repeated and vigorous nants ( Figure 4C ; data not shown). The very rapid onset of the ELAM-l-dependent adhesion to vascular endothelium exhibited by the CHO-FT cells is physiologically consistent with the speed of the analogous interaction between neutrophils and ELAM-1, which arrests these latter cells as they pass over activated endothelium.
Discussion
We have demonstrated here that expression of an a(1,3/ 1,4)fucosyltransferase results in the appearance of ligands for ELAM-1 on the surface of transfected COS-1 and CHO ceils. In COS-1 transfectants the sLex, Lex, Lea, and sLea oligosaccharides appeared at the surface, while in CHO transfectants only new sLex and Lex structures were detected. Thus, oligosaccharides terminating in the Lea and sLea structures are not necessary for expression of ELAMl-dependent cell adhesion. Moreover, ELAM-l-dependent adhesion was not manifested either by COS-1 cells transfected with pCDNAl-a(l,3)FT or by the variant of the HL-60 cell line when expression of the Lex determinant occurs in the absence of the sLex structure. We conclude that expression of a(1,3)fucosyltransferases capable of modifying acceptors containing a(2,3)sialic acid-substituted lactosaminoglycans is a critical step in the synthesis of the ligand(s) for ELAM-1. Therefore, one or more members of the family of sialylated, fucosylated lactosaminoglycans constructed by such enzymes are the most likely ligands for the CRD of ELAM-1.
The precise molecular nature of the ELAM-1 ligand(s) determined by the transfected fucosyltransferase cDNA remains to be elucidated. Likewise, the identities of the protein or lipid molecules that display the candidate oligosaccharide ligand(s) are as yet unknown. It is possible that the core structure of such underlying molecules may participate directly in the adhesion process. For example, the composite molecule might engage both the carbohydrate and putative complement regulatory domains of ELAM-1 and thereby possibly modulate complementmediated leukocyte-endothelial adhesion (Marks et al., 1969) . However, one can conclude that polylactosaminetype ganglioside precursors contained in normal myeloid cells (Fukudaet al., 1965) are not essential to the generation of ELAM-1 binding activity since the CHO host used for the stable transfection experiments does not construct such molecules (Smith et al., 1990) . As this observation suggests, the nonhematopoietic COS-1 and CHO cells are unlikely to express unique, myeloid-specific protein or lipid structures. In light of these considerations, we propose that the oligosaccharide moieties determined by the transfected cDNA are themselves sufficient to mediate ELAM-l-dependent adhesion. The slex structure and its mono-and polyfucosylated analogs are candidates for such molecules. Our attempts to assign binding activity to the slex tetrasaccharide determinant by antibody blocking approaches have been inconclusive because of the agglutinating nature of the IgM anti-slex antibody (R. M. M. and L. M. S., unpublished data). Detailed structural analyses of the oligosaccharide determinants at the surfaces of the ELAM-1 binding CHO transfectants should facilitate identification of the new oligosaccharide structures specified by the transfected fucosyltransferase cDNA. Once identified, these molecules may be isolated and tested individually for their ability to bind specifically to ELAM-1 and to inhibit its interaction with neutrophils. Alternatively, testing may be done on candidate molecules already purified by others from myeloid cells (Fukuda et al., 1964; Symington et al., 1965) . Recent advances in enzyme-catalyzed in vitro synthesis of oligosaccharides (Wong, 1969; Toone et al., 1969) , coupled with the emerging availability of cloned glycosyltransferase cDNAs (Paulson and Colley, 1969) should also facilitate the availability of these molecules for such analyses.
The fucosyltransferase encoded by pCDM%a(l,3/1,4FT), and used here to generate the ligand(s) for ELAM-1, represents the product of the human Lewis blood group locus (Kukowska-Latallo et al., 1990) . It exhibits a uniquely broad spectrum of acceptor substrate requirements that encompasses the requirements exhibited by members of two other general classes of a(l9)fucosyltransferases (Prieels et al., 1961; Palcic et al., 1969) . Expression of this enzyme is thought to be restricted to secretory epithelium, except in Lewis blood group negative individuals who inherit an inability to express this enzyme in any tissue (Watkins, 1960 ). This enzyme is thus probably not responsible for synthesis of the ELAM-1 ligand(s) in the myeloid lineage. The a(1,3)fucosyltransferase encoded by pCDNAia(l,3)FT is likewise not responsible since it is representative of a second distinct class of a(l,3)fucosyltransferases (Howard et al., 1967) unable to utilize a(2,3)sialic acidsubstituted lactosamine molecules, which are the apparent precursors for the ELAM-1 ligand(s). It therefore seems likely that a member of a third class of a(lB)fucosyltransferases, capable of constructing the Lex and sLex moieties but not the Lea isomers (Potvin et al., 1990) represents the enzyme that determines expression of the ELAM-1 ligand(s) in myeloid cells. Confirmation of this hypothesis will await the isolation and characterization of cloned gene segments or cDNAs that encode such an enzyme.
The observations presented here suggest the possibility that a leukocyte adhesion deficiency-like phenotype (Anderson and Springer, 1967) might occur in individuals with a genetic defect in the ability to express the appropriate a(1,3)fucosyltransferase in the myeloid lineage. In this context, it may be noted that many patients with adenocarcinema, but not healthy individuals, maintain circulating mucin-like molecules containing sLex moieties (Kannagi et al., 1966) . Such molecules are thought to be shed from malignant tumors in part as a consequence of the "aberrant" expression of the slex determinant frequently seen in association with malignant transformation (Fukushi et al., 1964; Fukushima et al., 1964; Kannagi et al., 1966) . Should such molecules participate in specific interactions with ELAM-1, it seems possible that they might act to inhibit normal interactions between leukocytes and the vascular wall, and thereby act to blunt inflammation-induced leukocyte recruitment in these patients. Given that adenocarcinoma cells have also been shown to exhibit ELAMl-dependent HUVEC adhesion (Rice and Bevilacqua, 1969) it is also interesting to consider the possibility that its oligosaccharide ligand(s) may participate in the metastatic process.
The extensive homology between the CRDs of the LEC-CAMKELECTIN family raises the possibility that the endogenous ligands for GMP140/PADGEM and LEC-CAM1 are structurally related to the sLex family of oligosaccharides. The former receptor, in particular, appears to interact with the same spectrum of normal cells and cell lines that adhere to ELAM-1 (Larsen et al., 198Qa) . Rosen and colleagues have demonstrated that the vascular ligand for gp90MEL14 is neuraminidase sensitive, suggesting that terminally linked sialic acid may represent a component of this ligand (Yednock and Rosen, 1989) . Of potential interest with respect to a fucosylated ligand for this molecule are studies implicating selective inhibition of functional activity with L-fucose, and fucoidan, a heteropolysaccharide rich in fucose4sulphate (Stoolman and Rosen, 1983; Stoolman et al., 1984) . In recent studies, a direct interaction between two fucose-sulphate-containing polysaccharides, fucoidan and the egg-jelly fucan, and purified gp90MEU4 has been demonstrated (Yasuyuki et al., 1990) . Perhaps these synthetic ligands mimic key structural features or the charge distribution of an endogenous fucosylated sialyl-lactosamine.
Thus, the identification of an endogenous carbohydrate determinant capable of interacting with ELAM-1 may provide important clues to the structure and synthesis of ligands for other members of the LEC-CAWSELECTIN family of adhesion molecules. Following their identification, these molecules, or their structural analogs, may find utility as specific therapeutic agents in inflammatory disease, in ischemia-reperfusion injury that often occurs as a concomitant of myocardial injury and stroke, and in other conditions in which LEC-CAMS contribute to leukocyte recruitment.
Experimental Pmcedures Cell Cultum
Human umbilical vein endothelial cells were isolated and propagated according to the method of Jaffe (Jaffe, 1964) . Cells were maintained in medium 199 with 20% fetal bovine serum, 100 fig/ml endothelial growth supplement (Collaborative Research), and 100 uglml bovine lung heparin (Sigma). Cells were used between passages 2 and 4. Endothelial identity was confirmed by the presence of typical morphology at confluence, by immunofluorescence with antibody to von Willebrand factor, and by uptake of acetylated low density lipoprotein. For adhs sion assays, HUVECs were passaged with trypsin/EDTA (GIBCO) and plated in 96-well plates (Dynatech, Method I; Falcon, Method II; see HUVEC Adhesion Assays section). Cells were allowed to grow to confluence for at least 2 days prior to use in adhesion assays. HL-60 lines in spinner culture were maintained between 2.5 x I@ and 15 x IO6 cells per ml in RPM1 1640 supplemented with 10% fetal calf serum and antibiotics. The CHO line Ade-C (Oates and Patterson, 1977; Van Keuren et al., 1986 ) was grown in a-modified Eagle's medium supplemented with 10% fetal calf serum. Transfected CHO cells were grown in media supplemented with G418 (GIBCO) at 400 pglml (active drug). COS-1 cells were grown in Dulbeccos modified Eagle's medium containing 10% fetal calf serum.
Glycoyltranafemae Exprerslon kton
Previous publications describe the plasmids pCDM7 and pCDM%aGT (Larsen et al., 1969b) , pCDMba(l,3/1,4)FT (Kukowska-Latallo et al., 1990 ) and pH3.4 (Rajan et al., 1989) . Plasmid pCDNAl-a(l,3)FT contains a 3.6 kb Pstl human genomic DNA restriction fragment that encodes an a(l,3)fucosyltransferase (J. B. L. et al., unpublished data). This fragment was isolated from a human lambda phage rescued from a genomic DNA library probed at low stringency with the insert in pCDMba(l,3/1,4)FT.
The gene segment is cloned in the appropriate transcriptional orientation into the mammalian expression vector pCDNA1 (InVitrogen).
Antlbodles
The anti-Lex antibody antiSSEA-(mouse monoclonal IgM as ascites; Salter and Knowles, 1976) was provided by Dr. D. Salter (Philadelphia). Anti-slex antibody CSLEXI (mouse monoclonal IgM, HPLC purified [Fukushima et al., 19841) and anti-slea antibody CSLEAl (mouse monoclonal lgG3, ammonium sulfate precipitate [Galton et al., 1985; Chia et al., 19651) were provided by Dr. F? Terasaki (Los Angeles). Anti-H and anti-Lea antibodies (both mouse monoclonal IgM, antigen affinity purified) were purchased from Chembiomed Ltd. (Edmonton). Anti-ELAM-1 antibody BBll (Benjamin et al., 1990) was the gift of Dr. Roy Lobb (Biogen, Inc., Cambridge, MA). IgG2b, anti-CDllb, anti-CD19, and anti-CD33 antibodies were purchased from Coulter Corp (Hialeah, FLA). Anti-VCAM antibody 489 (Carlos and Harlan, 1990) was provided by Dr. John Harlan (University of Washington, Seattle). Anti-ICAMI antibody 84HlO (Makgoba et al., 1966) was purchased from AMAC, Inc. Anti-HLA class I antibody V&/32 (Parham et al., 1979) was purchased from Sera-Lab, Inc. (England).
Transfactlon, 51Cr Labellng, and Harvesting of COW Cells COS-1 cells were transfected with various plasmids using the DEAEdextran procedure (Davis et al., 1966) as previously described (Larsen et al., 1969b) . Approximately 72 hr after transfection, cells (approximately 1 x 106) were labeled with 51Cr by incubating them for 3-4 hr with 10 uCi/ml Nas1Cr04 (NEN). Labeled or unlabeled, transfected COS-1 cells were harvested for HUVEC binding assays, or for flow cytometry analyses, by washing the cell monolayers with calcium, magnesium-free PBS (CMF-PBS) containing 2 mM EDlA, and then incubating the washed monolayers with CMF-PBS/P mM EDTA. Detached cells were washed once by centrifugation through CMF-PBS/P mM EDTA and then resuspended in buffers compatible with flow cytometry or binding analyses.
Constructlon and Wr Labeling of Stably Ransfected CHO Cell Lines
CHO Ade-C cells (Oates and Patterson, 1977; Van Keuren et al., 1986) were transfected (Chen and Okayama, 1967) with Xhol-linearized pCDM7-a(l,3/l,4)FT (Kukowska-Latallo et al., 1990) or with Xhollinearized pCDM7 (Larsen et al., 1969b) , each coprecipitated in a IOfold molar excess over EcoRI-linearized pSV2-Neo (Southern and Berg, 1982) . Approximately 26% of the G416-resistant transfectants generated with pCDM7-a(1,3/1,4)Ff stained positively with an anti-Lex antibody (anti-SSEA-I; Salter and Knowles, 1978) . A single, clonal, SSEA-l-positive cell line (CHO-FT) was derived from this population. The G4lEresistant transfectants generated with pCDM7 were maintained as an uncloned, pooled population (CHO-V). Cell extracts prepared from CHO-FT contained substantial amounts of a(l,3)fucosyltransferase activity when assayed with the acceptor N-acetyllactosamine (Kukowska-Latallo et al., 1990) . whereas extracts prepared from the parental cell line and from the CHO-V cells contained no detectable fucosyltransferase activity. CHO-FT or CHO-V (6 x 109 were labeled with slCr by incubating them for 5-6 hr in 25 uCi/ml NaslCr. Labeled cells were then harvested using the procedure described above for COS-1 cells.
HUVEC Adhesion Assays
Two methods were used for quantitating heterotypic adhesion to HUVEC monolayers.
Method I was used for analyses with transfected cells and is a conventional HUVEC adhesion assay utilizing 51Cr-labeled cells incubated at 37"C. HUVECs in 96well plates were placed in growth media without growth factors, with or without 20 @ml TNFa (Genentech), for 4 to 6 hr prior to binding assays. In experiments where inhibitory antibodies were used, antibodies were added in 50 pl of PBS containing a 100 ug/ml concentration each of Ca and Mg (PBSICalMg), 0.5% human serum albumin (endotoxin-free, Cutter), and incubated with HUVEC at 4OC for 1 hr. Antibodies were added to a final concentration of 1 &t/ml, except the anti-HLA class I antibody, which was ascites used at a I:1000 dilution. These represent saturating concentrations, as determined by radioimmunoassay. After treating with antibodies, HUVEC monolayers were washed three times with PBSICalMg. Cells to be tested for adhesion were harvested as detailed above, resuspended in PBSICalMg, and held at 4"C for the shortest time possible until used in the assay. Cells (3 x IO5 neutrophils [prepared as described by Marks et al., 19691 , 1 x 10s COS-1 cells, 3 x IO5 CHO cells) were added to HUVEC monolayers in 100 pl of PBSICalMg and incubated at 3pC. Microscopic titration was used to determine the numbers of cells added of each type (sufficient to just allow cells to form an essentially confluent monolayer overlying the HUVEC monolayer, providing the majority of added cells an opportunity to interact with the underlying endothelium without multilayering). Cells were allowed to adhere for various times (10 to 25 min; see figure legends). Unbound cells were removed by exchanging the wells three times with 150 ul of PBS/Ca/Mg. Each well was then counted in a gamma counter, and the number of bound cells was calculated based upon a previous determination of the number of cpms incorporated per radiolabeled cell.
Method II maximizes carbohydrate-dependent adhesion by adopting principles used to measure the lectin-dependent adhesion of lymphocytes to frozen sections of lymph nodes (Stoolman et al., 1967) . This method was used to determine ELAM-l-dependent adhesion of the HL-60 myeloid cell lines. HUVECs were plated in 96well tissue culture plates; 24 hr later, the confluent HUVEC monolayers were incubated with 20 nglml TNFa for 4-6 hr prior to initiating binding assays. HL-60 cells were washed in MEM+ (minimal essential medium buffered to pH 7.3 with Tricine [40 mM] and supplemented with 1 mglml bovine serum albumin) immediately prior to fixation. Immediately prior to the binding assay, cells in suspension were fixed in freshly prepared paraformaldehyde (0.5% paraformaldehyde in 0.15 M cacodylate buffer [pH 7.41; 20 min, 4OC), washed extensively, and resuspended at lo6 cells per ml in MEM+. In some experiments, the TNFa-treated HUVEC monolayers were preincubated at PC-1oOC with 50 ul of either IgGPb or BBll monoclonal antibodies at a concentration of 20 uglml. Fixed cells (lOs cells in 50 ul) were generally added directly to the plates after 15-30 min of preincubation (washing the HUVEC monolayers free of unbound antibody prior to instituting the binding assays had no effect on the level of inhibition; data not shown). Added cells were allowed to settle and interact with the HUVEC for 45 min at PC-IOOC prior to quantitation of adhesion. Unattached cells were removed by aspirating the cell suspensions and gently washing the monolayers three times with 200 ul of MEM+ at room temperature.
The wash solution was applied with an 6-channel multipipettor to the upper wall of the wells while maintaining the plates at a 30° angle. The solutions were then drawn off the lower wall without contacting the monolayer. The number of cells recovered from each well was determined by counting the pooled washes on a Coulter ZBI cell counter. The number of bound cells represents the difference between the number of cells applied to each well and the number recovered from the well.
Flow Cytometry
Transfected COS-1 cells, or CHO transfectants, were subjected to flow cytometry analysis with mouse monoclonal IgM antibodies directed against carbohydrate epitopes, using procedures described previously (Ernst et al., 1969; Kukowska-Latallo et al., 1990) . Cells were stained with saturating amounts of antiSSEAmonoclonal antibody (1:iOOO dilution of ascites), anti-Lea monoclonal antibody (10 uglml), anti-H antibody (10 ug/ml), or anti-CSLEXI (10 ug/ml). Cells were then stained with fluorescein-conjugated goat anti-mouse IgM (Sigma; 40 ug/ml) and subjected to analysis by flow cytometry on a FACScan (Becton Dickinson, Mountain View, CA) as described previously (Ernst et al., 1969; Larsen et al., 1969b) . Cell staining was measured in arbitraryfluorescent intensity units and was displayed on a four-decade log scale. Analyses with the lgG3 class mouse antiCSLEA antibody (10.6 uglml), or the pooled mouse IgG control antibody (Mslg, Coulter, 10 us/ml), were performed in an identical manner, except that an FITCconjugated goat anti-mouse IgG antibody (Sigma, 40 uglml) 
